Expression of inflammatory cytokines and effect of Aconitum leucostomum Worosch. in collagen-induced arthritis rats

doi:10.3969/j.issn.2095-4344.2015.18.002

Abstract

Abstract:

BACKGROUND: The majority of rheumatoid arthritis treatment is chronic anti-arthritis drugs, biological agents and plant drugs. Among them, plant drugs have been widely concerned due to low cost and few adverse effects.
OBJECTIVE: To observe the expression of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the synovium of collagen-induced arthritis rats, and explore the effect of Aconitum leucostomum Worosch. on the expression.
METHODS: Forty-five rats were randomly divided into normal control group (8 rats) and model group (37 rats). The collagen-induced arthritis model was established with the injection of type II bovine collagen into the end of the tail and paws. After the success of modeling, the 24 successful model rats were randomly selected and divided into model group (8 rats), Tripterygium wolfprdii polyglycoside group (8 rats) and Aconitum leucostomum Worosch. group (8 rats). The arthritis index of the rats in the three intervention groups and one control group were evaluated weekly. After treated by intragastric administration for 4 weeks (Tripterygium wolfprdii polyglycoside group and Aconitum leucostomum Worosch. group were taken by the corresponding drug solution, model group and normal control group were taken by the same volume of physiological saline), the expressions of TNF-α and IL-1β in the synovium were tested by immunohistochemistry.
RESULTS AND CONCLUSION: Compared with the model group, the arthritis index of mice in Tripterygium wolfprdii polyglycoside group and Aconitum leucostomum Worosch. group was decreased significantly after treatment (P < 0.05). The expression levels of TNF-α and IL-1β in the synovium of model group were significantly higher than those of the normal control group (P < 0.05). After treatment with Aconitum leucostomum Worosch. and Tripterygium wolfprdii polyglycoside, the expression levels of TNF-α and IL-1β in the synovium was decreased compared with the model group (P < 0.05). Experimental findings indicated that, the mechanism that Aconitum leucostomum Worosch. treats rheumatoid arthritis is related to the inhibition of TNF-α and IL-1β.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: Aconitum leucostomum Worosch., Arthritis, Experimental, Tumor Necrosis Factor-α, Interleukin-1β

CLC Number:

R318

Zhang Jun-yu, Du Wen-jing, Ji Peng, Liu Qing, Luo Li, Luo De-mei. Expression of inflammatory cytokines and effect of Aconitum leucostomum Worosch. in collagen-induced arthritis rats[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(18): 2794-2799.

Figures/Tables 3

References

[1] Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E3. Diagnosis and classification of rheumatoid arthritis. J Autoimmun. 2014;48-49:26-30.
[2] ScottDL, Wolfe F, Huizinga TW, et al. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108.
[3] 叶伟胜,张铁良.类风湿关节炎流行病学进展[J].国际骨科学杂志, 2009,3(3):144-147.
[4] endas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-αinhibitors. Arthritis Res Ther. 2011;13(1):25-28.
[5] Schleinitz N, Vély F, Harlé JR, et al. Natural killer cells in human autoimmune diseases. Immunology. 2010;131(4):451-458.
[6] Ohta S, Harigai M, Tanaka M, et al. Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. J Rheumatol. 2001;28(8):1756-1763
[7] Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology. 2002;41(9):972-980.
[8] Zwerina J, Redlich K, Schett G, et al. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci. 2005;1051:716-729.
[9] Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-279.
[10] Le Loët X, Nordstrëm D, Rodriguez M. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the omega trial. J Rheumatol. 2008;35(8):1538-1544.
[11] Voulgari, Paraskevi V, Drosos, et al. Adalimumab in the treatment of rheumatoid arthritis. Exp Opin Biol Ther. 2014; 14(4):549-561.
[12] Goldblatt F, Isenberg DA. New therapies for rheumatoid arthritis. J Allergy Clin Immunol. 2005;140(2):195-204.
[13] 吴沅皞,刘维.中成药治疗类风湿关节炎的实验研究近况[J].中华中医药杂志,2010,25(11):1846-1849.
[14] 徐新,巴哈尔古丽•黄尔汗.哈萨克药志(第一卷)[M].北京:民族出版社,2009.
[15] Han W, Xiong Y, Li Y, et al. Anti-arthritic effects of clematichinenoside (AR-6) on PI3K/Akt signaling pathway and TNF-α associated with collagen-induced arthritis. Pharm Biol. 2013;51(1):13-22.
[16] Cuzzocrea S, McDonald MC, Mota-Filipe H. Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of collagen-induced arthritis. Arthritis Rheuma. 2000;43(2):320-328.
[17] 刘悦,蔡冬梅,哈木拉提,等.哈药白喉乌头对小鼠的急性毒性实验研究[J].新疆医科大学学报,2011,(7):694-696.
[18] 应晓君,冯君.甲氨蝶呤对CIA大鼠滑膜IL-1β、IL-8、VEGF表达的影响[J].哈尔滨医药,2013,(3):170-172.
[19] 周强,吕厚山,栗占国.胶原诱导的关节炎动物模型研究现状及进展[J].中华风湿病学杂志,2003,7(4):227-231.
[20] 吾买尔夏提,魏岩.新疆药用乌头的民族植物学[J].中国野生植物资源杂志,2004,(4):29-30.
[21] Lv QW, Zhang FC. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. 2014. doi: 10.1136/annrheumdis-2013-204807.
[22] 薛蕾,闫德友.雷公藤化学成分、生物活性及其资源利用概述[J].青海农林科技,2013,(4):24-28.
[23] 赵翡翠;雷蕊;聂继红.分光光度法测定新疆不同产地白喉乌头不同部位总生物碱的含量[J].中药材,2013,(9):1406-1408.
[24] Chen BJ. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma. 2001;42(3): 253-265.
[25] 谢希,陈进伟,彭佑铭.抗肿瘤坏死因子α治疗类风湿关节炎致感染风险的Meta分析[J].中南大学学报(医学版),2013,(7): 722-736.
[26] 黄蓓,汪庆童,刘亢亢,等.类风湿关节炎发生发展中TNF-α信号通路与CD4+T细胞的关系[J].中国药理学通报,2013,(7): 900-903.
[27] Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20(27):1-13.
[28] Fox SW, Fuller K, Chambers TJ. Activation of osteoclasts by interleukin-1: divergent responsiveness in osteoclasts formed in vivo and in vitro. J Cell Physiol. 2000;184(3):334-340.
[29] Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis and Rheumatism. 2005;52(1):128-135.
[30] Coxon A, Bolon B, Estrada J, et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheuma. 2002;46(10):2604-2612.
[31] 王志中,王勇,方勇飞,等.血小板、与活动期类风湿关节炎的相关性研究[J].第三军医大学学报,2011,33(5):469-472